Teva Pharmaceuticals
 |
|
| Public | |
| Traded as | : TEVA : TEVA |
| Industry | Pharmaceutical |
| Founded | 1901 |
| Founder | Chaim Salomon Moshe Levin Yitschak Elstein |
| Headquarters | Petah Tikva, Israel |
|
Key people
|
|
| Products | Pharmaceuticals |
| Revenue |
 $20.3 billion USD (FY 2014) |
|
$3.951 billion USD (FY 2014) |
|
|
$3.055 billion USD (FY 2014) |
|
|
Number of employees
|
43,000 (2014) |
| Website |
www www |
Teva Pharmaceutical Industries Ltd. (Hebrew: טבע תעשיות פרמצבטיות בע"מ) is an Israeli multinational pharmaceutical company headquartered in Petah Tikva, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and to a lesser extent proprietary pharmaceuticals. It is the largest generic drug manufacturer in the world and one of the 15 largest pharmaceutical companies worldwide. Teva's facilities are located in Israel, North America, Europe, and South America. Teva stock trades on both the (via ADRs) and the , and is a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Teva's earliest predecessor was Salomon, Levin, and Elstein Ltd., a wholesale distributor based in Palestine that was founded in 1901. During the 1930s, new immigrants from Europe founded several pharmaceutical companies including Teva ("Nature" in Hebrew), Assia, and Zori. In 1951, Teva raised capital through the newly founded after the formation of the new country Israel.
In 1964, Assia and Zori merged and acquired a controlling interest in Teva. In 1976, these three companies merged into the modern Teva Pharmaceutical Industries Ltd. In 1980, Teva continued to follow its vision of becoming one of the world's biggest pharmaceutical companies by acquiring Ikapharm, then Israel's second largest drug manufacturer.
In 1982, Teva was granted approval by the U.S. Food and Drug Administration (FDA) for its Kfar Saba manufacturing plant, an essential milestone for marketing pharmaceuticals in the USA.
In 2005, Teva opened a new, state-of-the-art pharmaceutical manufacturing plant in Har Hotzvim, a technology park in Jerusalem. The plant received FDA approval in early 2007. Teva entered the Japanese market in 2005, and in 2008 established a generics joint venture with Kowa.
...
Wikipedia